HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date (Ascending) | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9064 | Cabazitaxel (Sandoz) | Cabazitaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2023 | Aug. 28, 2023 | In Use | ||
J9345 | Retifanlimab-dlwr | Zynyz | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2023 | Aug. 28, 2023 | In Use | ||
C9163 | Talquetamab | Talvey | 0.25mg | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | No | 2023 | Dec. 7, 2023 | April 17, 2024 | No Longer Used | |
C9165 | Elranatamab-bcmm | Elrexfio | 1mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2023 | Dec. 7, 2023 | April 17, 2024 | No Longer Used | |
J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec. 7, 2023 | In Use | ||
J9072 | Cyclophosphamide (Dr Reddy's) | Cyclophosphamide | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2023 | Dec. 7, 2023 | In Use | ||
J9172 | Docetaxel (Ingenus) | Docetaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2017 | Dec. 7, 2023 | In Use | ||
J9255 | Methotrexate (Accord) | Methotrexate | 50mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2014 | Dec. 7, 2023 | In Use | ||
J9258 | Paclitaxel (Teva) | Paclitaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2016 | Dec. 7, 2023 | In Use | ||
J9286 | Glofitamab-gxbm | Columvi | 2.5mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Dec. 7, 2023 | In Use |
Found 716 results in 4 milliseconds — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.